Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers

Conditions:   Lung Neoplasms;   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell;   Malignant Mesothelioma, Advanced;   Head and Neck Cancer;   Melanoma;   Merkel Cell Carcinoma;   Renal Cell Carcinoma;   Urothelial Carcinoma;   Classical Hodgkin Lymphoma
Intervention:   Drug: CK-301
Sponsors:   Checkpoint Therapeutics, Inc.;   Novotech (Australia) Pty Limited
Not yet recruiting - verified July 2017

http://ift.tt/2u4YsMl